Payment overview · 2025
General Payments
$216.62
11 reported records · 4 companies
Healthcare provider profile · identity verified
Alyssa Garner, CRNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · SHEFFIELD, AL · NPI 1780290858
Verified facts
What the public records show
CMS Open Payments records show Alyssa Garner, CRNP received $216.62 in general payments during 2025 across 11 reported records.
AstraZeneca Pharmaceuticals LP accounted for 71.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Linzess by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 93 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Symbicort by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $155.25 | 71.7% | 7 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $32.20 | 14.9% | 2 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $22.77 | 10.5% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $6.40 | 3.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $216.62 | 11 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $22.77 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $19.71 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $16.95 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $16.95 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $15.25 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $6.40 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
33 | 18 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
93 | 37 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
28 | 16 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 423 | 118 |
| Gabapentin | Gabapentin | 406 | 147 |
| Pantoprazole Sodium | Pantoprazole Sodium | 326 | 176 |
| Amlodipine Besylate | Amlodipine Besylate | 289 | 157 |
| Atorvastatin Calcium | Atorvastatin Calcium | 280 | 168 |
| Levothyroxine Sodium | Levothyroxine Sodium | 242 | 109 |
| Metformin Hcl | Metformin Hcl | 204 | 113 |
| Omeprazole | Omeprazole | 196 | 99 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 189 | 91 |
| Tramadol Hcl | Tramadol Hcl | 184 | 77 |
| Lisinopril | Lisinopril | 170 | 99 |
| Mounjaro | Tirzepatide | 167 | 45 |
| Hydrochlorothiazide | Hydrochlorothiazide | 156 | 72 |
| Losartan Potassium | Losartan Potassium | 145 | 80 |
| Pregabalin | Pregabalin | 138 | 36 |
| Metoprolol Succinate | Metoprolol Succinate | 133 | 72 |
| Potassium Chloride | Potassium Chloride | 130 | 78 |
| Montelukast Sodium | Montelukast Sodium | 127 | 60 |
| Simvastatin | Simvastatin | 126 | 56 |
| Duloxetine Hcl | Duloxetine Hcl | 122 | 55 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 121 | 59 |
| Furosemide | Furosemide | 118 | 70 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 117 | 45 |
| Allopurinol | Allopurinol | 107 | 55 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 107 | 58 |
| Carvedilol | Carvedilol | 100 | 53 |
| Escitalopram Oxalate | Escitalopram Oxalate | 97 | 48 |
| Farxiga | Dapagliflozin Propanediol | 93 | 37 |
| Meloxicam | Meloxicam | 93 | 57 |
| Pravastatin Sodium | Pravastatin Sodium | 92 | 58 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 90 | 49 |
| Methocarbamol | Methocarbamol | 87 | 57 |
| Fenofibrate | Fenofibrate | 86 | 40 |
| Metoprolol Tartrate | Metoprolol Tartrate | 83 | 43 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 81 | 44 |
| Fluticasone Propionate | Fluticasone Propionate | 80 | 42 |
| Januvia | Sitagliptin Phosphate | 80 | 29 |
| Azithromycin | Azithromycin | 78 | 68 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 78 | 35 |
| Hydralazine Hcl | Hydralazine Hcl | 78 | 37 |
| Trazodone Hcl | Trazodone Hcl | 77 | 43 |
| Trulicity | Dulaglutide | 76 | 25 |
| Glimepiride | Glimepiride | 75 | 48 |
| Tamsulosin Hcl | Tamsulosin Hcl | 75 | 43 |
| Zolpidem Tartrate | Zolpidem Tartrate | 73 | 24 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 72 | 33 |
| Eliquis | Apixaban | 65 | 37 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 65 | 36 |
| Fenofibrate | Fenofibrate Nanocrystallized | 64 | 31 |
| Clonazepam | Clonazepam | 61 | 21 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 60 | 31 |
| Methylprednisolone | Methylprednisolone | 60 | 51 |
| Citalopram Hbr | Citalopram Hydrobromide | 58 | 33 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 56 | 20 |
| Ropinirole Hcl | Ropinirole Hcl | 51 | 25 |
| Buspirone Hcl | Buspirone Hcl | 48 | 22 |
| Ozempic | Semaglutide | 48 | 19 |
| Alendronate Sodium | Alendronate Sodium | 47 | 27 |
| Celecoxib | Celecoxib | 47 | 21 |
| Ondansetron Odt | Ondansetron | 47 | 37 |
| Famotidine | Famotidine | 46 | 24 |
| Metformin Hcl Er | Metformin Hcl | 45 | 24 |
| Alprazolam | Alprazolam | 44 | 15 |
| Clopidogrel | Clopidogrel Bisulfate | 43 | 29 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 41 | 38 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 41 | 39 |
| Tizanidine Hcl | Tizanidine Hcl | 41 | 17 |
| Sertraline Hcl | Sertraline Hcl | 39 | 23 |
| Glipizide | Glipizide | 37 | 17 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 36 | 19 |
| Spironolactone | Spironolactone | 36 | 18 |
| Fluconazole | Fluconazole | 34 | 27 |
| Ezetimibe | Ezetimibe | 33 | 17 |
| Linzess | Linaclotide | 33 | 18 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 32 | 16 |
| Jardiance | Empagliflozin | 32 | 16 |
| Cefdinir | Cefdinir | 31 | 29 |
| Diclofenac Sodium | Diclofenac Sodium | 31 | 21 |
| Levetiracetam | Levetiracetam | 31 | 14 |
| Ondansetron Hcl | Ondansetron Hcl | 29 | 12 |
| Promethazine Hcl | Promethazine Hcl | 29 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 28 | 17 |
| Symbicort | Budesonide/Formoterol Fumarate | 28 | 16 |
| Topiramate | Topiramate | 28 | 13 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 27 | 20 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 26 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 26 | 12 |
| Ibuprofen | Ibuprofen | 25 | 11 |
| Lorazepam | Lorazepam | 25 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 25 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 25 | 14 |
| Propranolol Hcl | Propranolol Hcl | 24 | 15 |
| Sucralfate | Sucralfate | 24 | 12 |
| Atenolol | Atenolol | 23 | 13 |
| Megestrol Acetate | Megestrol Acetate | 23 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 23 | 20 |
| Bupropion Xl | Bupropion Hcl | 22 | 11 |
| Clindamycin Hcl | Clindamycin Hcl | 22 | 21 |
| Amiodarone Hcl | Amiodarone Hcl | 21 | 11 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 20 | suppressed |
| Lovastatin | Lovastatin | 20 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 20 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 19 | 18 |
| Meclizine Hcl | Meclizine Hcl | 19 | 15 |
| Nystatin | Nystatin | 19 | 12 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 19 | 16 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 19 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 18 | suppressed |
| Levofloxacin | Levofloxacin | 17 | 15 |
| Amitriptyline Hcl | Amitriptyline Hcl | 16 | suppressed |
| Chlorthalidone | Chlorthalidone | 16 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 16 | 13 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 16 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 15 | 11 |
| Benazepril Hcl | Benazepril Hcl | 14 | suppressed |
| Ramipril | Ramipril | 14 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 14 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 13 | suppressed |
| Clonidine | Clonidine | 13 | suppressed |
| Estradiol | Estradiol | 13 | suppressed |
| Finasteride | Finasteride | 13 | suppressed |
| Mupirocin | Mupirocin | 13 | 12 |
| Tresiba Flextouch U-100 | Insulin Degludec | 13 | suppressed |
| Valsartan | Valsartan | 13 | suppressed |
| Aripiprazole | Aripiprazole | 12 | suppressed |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Myrbetriq | Mirabegron | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Primidone | Primidone | 12 | suppressed |
| Xarelto | Rivaroxaban | 12 | suppressed |
| Lactulose | Lactulose | 11 | suppressed |
| Livalo | Pitavastatin Calcium | 11 | suppressed |
| Mirtazapine | Mirtazapine | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $216.62 · 11 records | AstraZeneca Pharmaceuticals LP | BREZTRI, Ohtuvayre, QULIPTA, UBRELVY, VOQUEZNA, VRAYLAR | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error